Akili Interactive's workforce strategy from 2020 through mid-2024 has been characterized by a pronounced and accelerating contraction, reflecting significant operational restructuring and a fundamental strategic pivot. Beginning in September 2023, the company initiated a substantial reduction, cutting 30-40% of its staff to facilitate a shift towards a non-prescription model for its digital therapeutics. This trend intensified dramatically into 2024, with a reported sales slump prompting further strategic re-evaluation. By April 2024, Akili executed a 46% workforce layoff, signaling deepening challenges. The most recent action in May 2024 saw another 40% of the workforce eliminated, explicitly tied to a definitive pivot towards selling digital therapeutics over the counter. This aggressive downsizing underscores a clear corporate imperative to streamline operations and reallocate resources towards a direct-to-consumer, non-prescription market approach, driven by efficiency demands and market performance pressures. The cumulative effect is a significantly leaner organization focused on a revised commercialization pathway.